ARTICLE | Product Development
Nuclear pacifism
Abbott data on HCV combo show cocktails don't need nucleotide-based inhibitor
October 22, 2012 7:00 AM UTC
Phase IIb data released by Abbott Laboratories last week provide the most compelling argument to date that all-oral HCV cocktails do not require a nucleotide-based NS5B inhibitor.
An abstract released ahead of the American Association for the Study of Liver Diseases (AASLD) meeting showed the pharma's five-drug nuc-free cocktail produced one of the highest SVR rates seen thus far in an interferon-free all-oral cocktail, and the highest in patients who were null responders to IFN-based therapy...